{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:14:48Z","timestamp":1794060888697,"version":"4.8.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["5R01EB025192-06"],"award-info":[{"award-number":["5R01EB025192-06"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA269787-01"],"award-info":[{"award-number":["CA269787-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01 CA248736"],"award-info":[{"award-number":["1R01 CA248736"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["I-2123-20220031"],"award-info":[{"award-number":["I-2123-20220031"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SIEGWA18XX0"],"award-info":[{"award-number":["SIEGWA18XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6629-21"],"award-info":[{"award-number":["6629-21"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL156647"],"award-info":[{"award-number":["R01HL156647"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41565-024-01680-8","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T10:01:55Z","timestamp":1716458515000},"page":"1409-1417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells"],"prefix":"10.1038","volume":"19","author":[{"given":"Xizhen","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-6095","authenticated-orcid":false,"given":"Yehui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Dilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-7479","authenticated-orcid":false,"given":"Yufen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-5269","authenticated-orcid":false,"given":"Xiaoyan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chieh","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-2950","authenticated-orcid":false,"given":"Rachel M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalin","family":"Mayberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-2466","authenticated-orcid":false,"given":"Samuel","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-0822","authenticated-orcid":false,"given":"Xiaoye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-5486","authenticated-orcid":false,"given":"Lindsay T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-5645","authenticated-orcid":false,"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-1931","authenticated-orcid":false,"given":"Daniel J.","family":"Siegwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature25022","volume":"553","author":"E Laurenti","year":"2018","unstructured":"Laurenti, E. & Gottgens, B. From haematopoietic stem cells to complex differentiation landscapes. Nature 553, 418\u2013426 (2018).","journal-title":"Nature"},{"key":"1680_CR2","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood-2006-03-006908","volume":"108","author":"TR Bauer Jr.","year":"2006","unstructured":"Bauer, T. R. Jr. et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 108, 3313\u20133320 (2006).","journal-title":"Blood"},{"key":"1680_CR3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"RM Blaese","year":"1995","unstructured":"Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4\u2009years. Science 270, 475\u2013480 (1995).","journal-title":"Science"},{"key":"1680_CR4","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","volume":"363","author":"K Boztug","year":"2010","unstructured":"Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918\u20131927 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR5","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bbmt.2019.12.589","volume":"26","author":"MJ Cowan","year":"2020","unstructured":"Cowan, M. J. et al. Early outcome of a phase I\/II clinical trial (NCT03538899) of gene-corrected autologous CD34+ hematopoietic cells and low-exposure busulfan in newly diagnosed patients with Artemis-deficient severe combined immunodeficiency (ART-SCID). Biol. Blood Marrow Transpl. 26, S88\u2013S89 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1680_CR6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","volume":"364","author":"HB Gaspar","year":"2004","unstructured":"Gaspar, H. B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181\u20132187 (2004).","journal-title":"Lancet"},{"key":"1680_CR7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter, J. et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N. Engl. J. Med. 386, 617\u2013628 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR8","doi-asserted-by":"crossref","first-page":"648951","DOI":"10.3389\/fimmu.2021.648951","volume":"12","author":"LA Kohn","year":"2021","unstructured":"Kohn, L. A. & Kohn, D. B. Gene therapies for primary immune deficiencies. Front. Immunol. 12, 648951 (2021).","journal-title":"Front. Immunol."},{"key":"1680_CR9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev.immunol.21.120601.141007","volume":"21","author":"M Kondo","year":"2003","unstructured":"Kondo, M. et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev. Immunol. 21, 759\u2013806 (2003).","journal-title":"Annu Rev. Immunol."},{"key":"1680_CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli, F. et al. Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia. N. Engl. J. Med. 386, 415\u2013427 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR11","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","volume":"94","author":"HL Malech","year":"1997","unstructured":"Malech, H. L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl Acad. Sci. USA 94, 12133\u201312138 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1680_CR12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","volume":"21","author":"RA Morgan","year":"2017","unstructured":"Morgan, R. A., Gray, D., Lomova, A. & Kohn, D. B. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell 21, 574\u2013590 (2017).","journal-title":"Cell Stem Cell"},{"key":"1680_CR13","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","volume":"140","author":"CD Sago","year":"2018","unstructured":"Sago, C. D. et al. Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution. J. Am. Chem. Soc. 140, 17095\u201317105 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1680_CR14","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","volume":"23","author":"D Shi","year":"2023","unstructured":"Shi, D., Toyonaga, S. & Anderson, D. G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 23, 2938\u20132944 (2023).","journal-title":"Nano Lett."},{"key":"1680_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/17425247.2011.553218","volume":"8","author":"K Sou","year":"2011","unstructured":"Sou, K., Goins, B., Oyajobi, B. O., Travi, B. L. & Phillips, W. T. Bone marrow-targeted liposomal carriers. Expert Opin. Drug Deliv. 8, 317\u2013328 (2011).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1680_CR16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.104.074534","volume":"312","author":"K Sou","year":"2005","unstructured":"Sou, K., Klipper, R., Goins, B., Tsuchida, E. & Phillips, W. T. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. J. Pharmacol. Exp. Ther. 312, 702\u2013709 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1680_CR17","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1021\/jacs.2c02706","volume":"144","author":"L Xue","year":"2022","unstructured":"Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926\u20139937 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1680_CR18","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2014-09-570192","volume":"125","author":"PE Boulais","year":"2015","unstructured":"Boulais, P. E. & Frenette, P. S. Making sense of hematopoietic stem cell niches. Blood 125, 2621\u20132629 (2015).","journal-title":"Blood"},{"key":"1680_CR19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fphys.2020.00848","volume":"11","author":"N Ikonomi","year":"2020","unstructured":"Ikonomi, N., Kuhlwein, S. D., Schwab, J. D. & Kestler, H. A. Awakening the HSC: dynamic modeling of HSC maintenance unravels regulation of the TP53 pathway and quiescence. Front. Physiol. 11, 848 (2020).","journal-title":"Front. Physiol."},{"key":"1680_CR20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.exphem.2011.01.008","volume":"39","author":"J Li","year":"2011","unstructured":"Li, J. Quiescence regulators for hematopoietic stem cell. Exp. Hematol. 39, 511\u2013520 (2011).","journal-title":"Exp. Hematol."},{"key":"1680_CR21","doi-asserted-by":"crossref","first-page":"621214","DOI":"10.3389\/fcell.2021.621214","volume":"9","author":"Y Man","year":"2021","unstructured":"Man, Y., Yao, X., Yang, T. & Wang, Y. Hematopoietic stem cell niche during homeostasis, malignancy, and bone marrow transplantation. Front. Cell Dev. Biol. 9, 621214 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1680_CR22","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1242\/dev.106575","volume":"141","author":"A Nakamura-Ishizu","year":"2014","unstructured":"Nakamura-Ishizu, A., Takizawa, H. & Suda, T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 141, 4656\u20134666 (2014).","journal-title":"Development"},{"key":"1680_CR23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086\u20131093 (2011).","journal-title":"Nat. Med."},{"key":"1680_CR24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"1680_CR25","volume":"8","author":"T Mandal","year":"2018","unstructured":"Mandal, T., Beck, M., Kirsten, N., Linden, M. & Buske, C. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci. Rep. 8, 989 (2018).","journal-title":"Sci. Rep."},{"key":"1680_CR26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.beha.2012.10.003","volume":"25","author":"S Pei","year":"2012","unstructured":"Pei, S. & Jordan, C. T. How close are we to targeting the leukemia stem cell? Best Pract. Res. Clin. Haematol. 25, 415\u2013418 (2012).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"1680_CR27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/0008-5472.CAN-19-1044","volume":"80","author":"C Li","year":"2020","unstructured":"Li, C. et al. Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models. Cancer Res. 80, 549\u2013560 (2020).","journal-title":"Cancer Res."},{"key":"1680_CR28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","volume":"5","author":"C Li","year":"2021","unstructured":"Li, C. et al. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal globin in beta-YAC mice. Blood Adv. 5, 1122\u20131135 (2021).","journal-title":"Blood Adv."},{"key":"1680_CR29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2020.09.001","volume":"29","author":"C Li","year":"2021","unstructured":"Li, C. et al. In vivo HSC gene therapy using a bi-modular HDAd5\/35++ vector cures sickle cell disease in a mouse model. Mol. Ther. 29, 822\u2013837 (2021).","journal-title":"Mol. Ther."},{"key":"1680_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omtm.2021.12.003","volume":"24","author":"C Li","year":"2022","unstructured":"Li, C. et al. Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5\/35++ vectors. Mol. Ther. Methods Clin. Dev. 24, 127\u2013141 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1680_CR31","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood.2020010020","volume":"138","author":"N Psatha","year":"2021","unstructured":"Psatha, N. et al. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood 138, 1540\u20131553 (2021).","journal-title":"Blood"},{"key":"1680_CR32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/10430349950018364","volume":"10","author":"DA Muruve","year":"1999","unstructured":"Muruve, D. A., Barnes, M. J., Stillman, I. E. & Libermann, T. A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965\u2013976 (1999).","journal-title":"Hum. Gene Ther."},{"key":"1680_CR33","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.2023019922","volume":"141","author":"CL Sweeney","year":"2023","unstructured":"Sweeney, C. L. & De Ravin, S. S. The promise of in vivo HSC prime editing. Blood 141, 2039\u20132040 (2023).","journal-title":"Blood"},{"key":"1680_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/hum.1997.8.1-37","volume":"8","author":"S Worgall","year":"1997","unstructured":"Worgall, S., Wolff, G., Falck-Pedersen, E. & Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37\u201344 (1997).","journal-title":"Hum. Gene Ther."},{"key":"1680_CR35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1680_CR37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1680_CR38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1680_CR39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1680_CR40","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202006619","volume":"33","author":"L Farbiak","year":"2021","unstructured":"Farbiak, L. et al. All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo. Adv. Mater. 33, e2006619 (2021).","journal-title":"Adv. Mater."},{"key":"1680_CR41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat. Mater. 20, 701\u2013710 (2021).","journal-title":"Nat. Mater."},{"key":"1680_CR42","doi-asserted-by":"crossref","first-page":"21321","DOI":"10.1021\/jacs.1c09822","volume":"143","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J. Am. Chem. Soc. 143, 21321\u201321330 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"1680_CR43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."},{"key":"1680_CR44","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei, T., Cheng, Q., Min, Y. L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11, 3232 (2020).","journal-title":"Nat. Commun."},{"key":"1680_CR45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","volume":"17","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777\u2013787 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"1680_CR46","first-page":"1183","volume":"108","author":"LC Wu","year":"2006","unstructured":"Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 1183\u20131188 (2006).","journal-title":"Blood"},{"key":"1680_CR47","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/bloodadvances.2019000820","volume":"3","author":"JY Metais","year":"2019","unstructured":"Metais, J. Y. et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 3, 3379\u20133392 (2019).","journal-title":"Blood Adv."},{"key":"1680_CR48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","volume":"595","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295\u2013302 (2021).","journal-title":"Nature"},{"key":"1680_CR49","doi-asserted-by":"crossref","first-page":"e1241854","DOI":"10.1080\/23723556.2016.1241854","volume":"5","author":"V Stavropoulou","year":"2018","unstructured":"Stavropoulou, V., Peters, A. & Schwaller, J. Aggressive leukemia driven by MLL-AF9. Mol. Cell Oncol. 5, e1241854 (2018).","journal-title":"Mol. Cell Oncol."},{"key":"1680_CR50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41565-019-0600-1","volume":"15","author":"X Hou","year":"2020","unstructured":"Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41\u201346 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1680_CR51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113654","volume":"223","author":"M Morales-Tenorio","year":"2021","unstructured":"Morales-Tenorio, M. et al. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. Eur. J. Med. Chem. 223, 113654 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1680_CR52","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/s41565-023-01416-0","volume":"18","author":"Y Zuo","year":"2023","unstructured":"Zuo, Y. et al. Controlled delivery of a neurotransmitter-agonist conjugate for functional recovery after severe spinal cord injury. Nat. Nanotechnol. 18, 1230\u20131240 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"1680_CR53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","volume":"21","author":"L Boike","year":"2022","unstructured":"Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881\u2013898 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1680_CR54","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1073\/pnas.1520756113","volume":"113","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl Acad. Sci. USA 113, 520\u2013525 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1680_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nn.2467","volume":"13","author":"L Madisen","year":"2010","unstructured":"Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133\u2013140 (2010).","journal-title":"Nat. Neurosci."},{"key":"1680_CR56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"1680_CR57","doi-asserted-by":"crossref","first-page":"eabf4398","DOI":"10.1126\/sciadv.abf4398","volume":"7","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).","journal-title":"Sci. Adv."},{"key":"1680_CR58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","volume":"52","author":"OM Enache","year":"2020","unstructured":"Enache, O. M. et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat. Genet. 52, 662\u2013668 (2020).","journal-title":"Nat. Genet."},{"key":"1680_CR59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"1680_CR60","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz, M. L. et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat. Genet. 53, 895\u2013905 (2021).","journal-title":"Nat. Genet."},{"key":"1680_CR61","doi-asserted-by":"crossref","unstructured":"Mayuranathan, T. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat. Genet. 55, 1210\u20131220 (2023).","DOI":"10.1038\/s41588-023-01434-7"},{"key":"1680_CR62","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cell.2020.10.025","volume":"183","author":"MV Zuccaro","year":"2020","unstructured":"Zuccaro, M. V. et al. Allele-specific chromosome removal after Cas9 cleavage in human embryos. Cell 183, 1650\u20131664e1615 (2020).","journal-title":"Cell"},{"key":"1680_CR63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1680_CR64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41587-020-0412-8","volume":"38","author":"SM Miller","year":"2020","unstructured":"Miller, S. M. et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat. Biotechnol. 38, 471\u2013481 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1680_CR65","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1680_CR66","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436\u2013443 (2023).","journal-title":"Science"},{"key":"1680_CR67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ardp.201400449","volume":"348","author":"R Marschalek","year":"2015","unstructured":"Marschalek, R. MLL leukemia and future treatment strategies. Arch. Pharm. 348, 221\u2013228 (2015).","journal-title":"Arch. Pharm."},{"key":"1680_CR68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ccell.2016.05.011","volume":"30","author":"V Stavropoulou","year":"2016","unstructured":"Stavropoulou, V. et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell 30, 43\u201358 (2016).","journal-title":"Cancer Cell"},{"key":"1680_CR69","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ncb3158","volume":"17","author":"X Kang","year":"2015","unstructured":"Kang, X. et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat. Cell Biol. 17, 665\u2013677 (2015).","journal-title":"Nat. Cell Biol."},{"key":"1680_CR70","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s43018-021-00262-0","volume":"2","author":"G Wu","year":"2021","unstructured":"Wu, G. et al. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2\u2013cFLIP\u2013NF-\u03baB signaling axis. Nat. Cancer 2, 1170\u20131184 (2021).","journal-title":"Nat. Cancer"},{"key":"1680_CR71","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11095","volume":"485","author":"J Zheng","year":"2012","unstructured":"Zheng, J. et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 485, 656\u2013660 (2012).","journal-title":"Nature"},{"key":"1680_CR72","volume":"11","author":"SS Itskovich","year":"2020","unstructured":"Itskovich, S. S. et al. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat. Commun. 11, 2369 (2020).","journal-title":"Nat. Commun."},{"key":"1680_CR73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931050","volume":"12","author":"IV Barreto","year":"2022","unstructured":"Barreto, I. V. et al. Leukemic stem cell: a mini-review on clinical perspectives. Front. Oncol. 12, 931050 (2022).","journal-title":"Front. Oncol."},{"key":"1680_CR74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01680-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01680-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01680-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T13:00:14Z","timestamp":1726664414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01680-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1038\/s41565-024-01680-8","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UT Southwestern has filed patent applications on the technologies described in this manuscript with X. Lian and D.J.S. listed as inventors. D.J.S. discloses the following competing interests: ReCode Therapeutics, Signify Bio, Tome Biosciences, Jumble Therapeutics and Pfizer Inc. D.R.L. is a consultant and equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver gene-editing or epigenome-modulating agents. M.J.W. is a consultant for GlaxoSmithKline, Cellarity, Novartis and Dyne Therapeutics. J.S.Y. is an equity owner of Beam Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}